Not Just a Biomarker: YKL-40 Links Glial Clock to Amyloidosis
This astrocytic glycoprotein greases glial phagocytosis and reduces plaque burden in mice. The circadian clock protein Bmal1 suppresses it.
ALL NEWS
5744 RESULTS
Sort By:
Epoxide Hydrolase, a Fat New Target for Alzheimer’s Therapy?
The enzyme degrades anti-inflammatory fatty acids in the brain. Blocking it with a brain-penetrant small molecule calmed A1 astrocytes, synapse-eating microglia, and improved amyloidosis and cognition in a mouse model.
Plasma NT1: This Tau Snippet Predicts Cognitive Decline in Alzheimer’s
Among a growing number of blood-based tauopathy markers, this new immunoassay may offer a way to catch preclinical disease just before symptoms show up.
In DIAN-TU, Gantenerumab Brings Down Tau. By a Lot. Open Extension Planned
Data shown at AAT-AD/PD explain why the DIAN-TU trial missed its primary endpoint. But gantenerumab strongly reduced plaques, tau, phospho-tau, and slowed NfL. This result prompted an open-label extension, sustaining hope for efficacy.
Getting Under Your Skin: Does Vitiligo Elevate Dementia Risk?
In a retrospective study, people with vitiligo had 12 times the risk of developing Alzheimer’s disease than did healthy controls. Why is that?
Begone 2020: Despite COVID, Alzheimer’s Research Advanced
Confronting unprecedented challenges this past year, scientists found ways to tide their research over and keep clinical trials mostly on track.
Amyloid Clearance: Check. Cognitive Benefit: Um … Maybe.
Plaque-busting antibodies reset the time course of amyloid accumulation, but so far provide only hints of a clinical benefit in mild AD. Good news: once gone, plaque stays gone for a while.
New Ways to Target Aβ and BACE Show Promising Phase 1 Data
BACE inhibitors are shaping up; pyroglutamate Aβ antibody clears plaques without ARIA, but immune reaction raises a flag.
RIP: Serotonin Receptor 5-HT6 Antagonist
Publication of negative results of Phase 3 idalopirdine trials lays to rest yet another candidate drug.
Most Detailed Look Yet at Activation States of Human Microglia
Single-cell RNA sequencing of 16,000 live microglia freshly isolated from human brain reveals nine distinct subtypes. One fades in Alzheimer’s. Why?
Mounting Modifications Move Tau Toward Aggregation in Alzheimer’s Brain
Quantifying 95 post-translational modifications of tau extracted from AD and control brains, a proteomics study proposes a “processive” model of phosphorylation, ubiquitination, acetylation that drive aggregation and map to distinct stages of disease.
Fatal Gift Wrap: Neurons Fall for Packaged Tau Oligomers
Neurons take up extracellular vesicles containing tau oligomers more readily than they do free tau. Some gift: This speeds the march of tauopathy through mouse brain.
Aβ Binds Glutamate Receptors. Only in Guys, Though.
In both mice and (wo)men, the sex difference comes down to an Aβ-glutamate receptor-prion protein troika.
Proteomics Uncovers Potential Markers, Subtypes of Alzheimer’s
Changes in the composition of the cerebrospinal fluid and synapses may reveal novel insights into AD pathology.
Herpes Triggers Amyloid—Could This Virus Fuel Alzheimer’s?
Herpes viruses that are commonly found in human brain promote rapid Aβ fibrillization and deposition in AD model systems.
Current Filters
- Date Range : All x